81 related articles for article (PubMed ID: 7772651)
1. Serotonergic responsivity in trichotillomania: neuroendrocrine effects of m-chlorophenylpiperazine.
Stein DJ; Hollander E; Cohen L; Simeon D; Aronowitz B
Biol Psychiatry; 1995 Mar; 37(6):414-6. PubMed ID: 7772651
[No Abstract] [Full Text] [Related]
2. Effect of serum cholesterol levels on meta-chlorophenylpiperazine-evoked neuroendocrine responses in healthy subjects.
Terao T; Yoshimura R; Ohmori O; Takano T; Takahashi N; Iwata N; Suzuki T; Abe K
Biol Psychiatry; 1997 May; 41(9):974-8. PubMed ID: 9110103
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity of serotonergic response in treatment-refractory schizophrenia patients.
Lindenmayer JP; Adityanjee ; Vital-Herne M; Bark N; Grochowski S; Moynihan N
Biol Psychiatry; 1997 Jul; 42(1):6-12. PubMed ID: 9193736
[TBL] [Abstract][Full Text] [Related]
4. Estrogen augments serotonergic activity in postmenopausal women.
Halbreich U; Rojansky N; Palter S; Tworek H; Hissin P; Wang K
Biol Psychiatry; 1995 Apr; 37(7):434-41. PubMed ID: 7786956
[TBL] [Abstract][Full Text] [Related]
5. Hormonal, psychological, and alcohol craving changes after m-chlorophenylpiperazine administration in alcoholics.
Buydens-Branchey L; Branchey M; Fergeson P; Hudson J; McKernin C
Alcohol Clin Exp Res; 1997 Apr; 21(2):220-6. PubMed ID: 9113256
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile.
Feuchtl A; Bagli M; Stephan R; Frahnert C; Kölsch H; Kühn KU; Rao ML
Pharmacopsychiatry; 2004 Jul; 37(4):180-8. PubMed ID: 15467976
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine and behavioral responses to intravenous m-chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects.
Anand A; Charney DS; Delgado PL; McDougle CJ; Heninger GR; Price LH
Am J Psychiatry; 1994 Nov; 151(11):1626-30. PubMed ID: 7943451
[TBL] [Abstract][Full Text] [Related]
8. Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects.
Klein E; Zohar J; Geraci MF; Murphy DL; Uhde TW
Biol Psychiatry; 1991 Nov; 30(10):973-84. PubMed ID: 1756202
[TBL] [Abstract][Full Text] [Related]
9. Evidence for a decline with age in behavioral responsivity to the serotonin agonist, m-chlorophenylpiperazine, in healthy human subjects.
Lawlor BA; Sunderland T; Hill JL; Mellow AM; Molchan SE; Mueller EA; Jacobsen FM; Murphy DL
Psychiatry Res; 1989 Jul; 29(1):1-10. PubMed ID: 2772095
[TBL] [Abstract][Full Text] [Related]
10. Ethanol substitutes for the discriminative stimulus effects of m-chlorophenylpiperazine.
Gatch MB
Brain Res; 2005 Nov; 1062(1-2):161-5. PubMed ID: 16256082
[TBL] [Abstract][Full Text] [Related]
11. Hormonal and subjective responses to intravenous meta-chlorophenylpiperazine in bulimia nervosa.
Levitan RD; Kaplan AS; Joffe RT; Levitt AJ; Brown GM
Arch Gen Psychiatry; 1997 Jun; 54(6):521-7. PubMed ID: 9193192
[TBL] [Abstract][Full Text] [Related]
12. Allelic variants of the serotonin(2C) receptor and neuroendocrinological responses to the serotonin(2C) receptor agonist m-chlorophenylpiperazine in healthy male volunteers.
Kühn KU; Quednow BB; Bagli M; Meyer K; Feuchtl A; Westheide J; Frahnert C; Maier W; Rao ML
Pharmacopsychiatry; 2002 Nov; 35(6):226-30. PubMed ID: 12518270
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine effects of M-chlorophenylpiperazine, a serotonin agonist, in humans.
Mueller EA; Murphy DL; Sunderland T
J Clin Endocrinol Metab; 1985 Dec; 61(6):1179-84. PubMed ID: 4055985
[TBL] [Abstract][Full Text] [Related]
14. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder.
Pigott TA; Zohar J; Hill JL; Bernstein SE; Grover GN; Zohar-Kadouch RC; Murphy DL
Biol Psychiatry; 1991 Mar; 29(5):418-26. PubMed ID: 2018816
[TBL] [Abstract][Full Text] [Related]
15. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers.
Hollander E; DeCaria CM; Nitescu A; Gully R; Suckow RF; Cooper TB; Gorman JM; Klein DF; Liebowitz MR
Arch Gen Psychiatry; 1992 Jan; 49(1):21-8. PubMed ID: 1728249
[TBL] [Abstract][Full Text] [Related]
16. Serotonin function in schizophrenia: effects of meta-chlorophenylpiperazine in schizophrenic patients and healthy subjects.
Kahn RS; Siever LJ; Gabriel S; Amin F; Stern RG; DuMont K; Apter S; Davidson M
Psychiatry Res; 1992 Jul; 43(1):1-12. PubMed ID: 1332094
[TBL] [Abstract][Full Text] [Related]
17. Responses to mCPP stimulation in depressed patients.
Thakore JH
Am J Psychiatry; 1995 Dec; 152(12):1833-4; author reply 1834-5. PubMed ID: 8526261
[No Abstract] [Full Text] [Related]
18. Plasma levels of m-chlorophenylpiperazine following single oral dose administration of m-chlorophenylpiperazine and trazodone in human volunteers.
Lawlor BA; Radcliffe J; Martinez R; Sunderland T; Murphy DL
Biol Psychiatry; 1997 Mar; 41(6):756-7. PubMed ID: 9067003
[No Abstract] [Full Text] [Related]
19. Hormonal and temperature responses to the 5-HT1A receptor agonist flesinoxan in normal volunteers.
Pitchot W; Wauthy J; Hansenne M; Pinto E; Fuchs S; Reggers J; Legros JJ; Ansseau M
Psychopharmacology (Berl); 2002 Oct; 164(1):27-32. PubMed ID: 12373416
[TBL] [Abstract][Full Text] [Related]
20. Hormonal responses to meta-chlorophenylpiperazine (m-CPP) are undiminished by acute m-CPP pretreatment.
Coccaro EF; Kavoussi RJ; Trestman RL; Gabriel SM; Cooper TB; Siever LJ
Psychiatry Res; 1996 May; 62(2):139-45. PubMed ID: 8771611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
